Sökning: "Lymphoid malignancies"

Visar resultat 1 - 5 av 53 avhandlingar innehållade orden Lymphoid malignancies.

1. 1. Recurrent Genetic Mutations in Lymphoid Malignancies

   Författare :Emma Young; Richard Rosenquist; Larry Mansouri; Lesley Ann Sutton; Dimitar Efremov; Uppsala universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Lymphoid malignancies; mutations; CLL; stereotypy; subsets; PMBL; NFKBIE; EGR2; whole-genome sequencing; Molekylär genetik; Molecular Genetics; Oncology; Onkologi;

   Sammanfattning : In recent years, the genetic landscape of B-cell derived lymphoid malignancies, including chronic lymphocytic leukemia (CLL), has been rapidly unraveled, identifying recurrent genetic mutations with potential clinical impact. Interestingly, ~30% of all CLL patients can be assigned to more homogeneous subsets based on the expression of a similar or “stereotyped” B-cell receptor (BcR). LÄS MER

3. 2. Prognostic markers and DNA methylation profiling in lymphoid malignancies

   Författare :Sujata Bhoi; Richard Rosenquist Brandell; H Denis Alexander; Uppsala universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Lymphoid malignancies; CLL; MCL; prognostic markers; micro-RNA; methylation; stereotyped subsets;

   Sammanfattning : In recent years, great progress has been achieved towards identifying novel biomarkers in lymphoid malignancies, including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), at the genomic, transcriptomic and epigenomic level for accurate risk-stratification and prediction of treatment response. In paper I, we validated the prognostic relevance of a recently proposed RNA-based marker in CLL, UGT2B17, and analyzed its expression levels in 253 early-stage patients. LÄS MER

4. 3. Molecular genetics of lymphoid malignancies

   Författare :Mats Merup; Karolinska Institutet; Karolinska Institutet; []
   Nyckelord :;

   Sammanfattning : Advances in molecular genetics during the last decade has made it possible to identify genetic lesions in malignant cells that are specific for disease entities with a common clinical presentation and prognosis. In chronic lymphocytic leukemia (CLL) deletions in 13ql4 are the most frequently occurring abnormalities and deletions cluster around marker D13S319 suggesting that a tumor suppressor gene is located in this region. LÄS MER

5. 4. Molecular epidemiology approach : nested case-control studies in glioma and lymphoid malignancies

   Författare :Florentin Späth; Beatrice S. Melin; Carl Wibom; Ann Sofie Johansson; Ingvar Bergdahl; Ola Landgren; Umeå universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Glioma; B cell lymphoma; multiple myeloma; risk; repeated samples; prospective longitudinal study; nested case-control study; circulating sEGFR and sERBB2; circulating immune markers and growth factors; marker disease association; disease progression; NSHDS; Janus; linear mixed modeling; epidemiologi; Epidemiology; Oncology; onkologi;

   Sammanfattning : BACKGROUND: Nested case-control studies aim to link molecular markers with a certain outcome. Repeated prediagnostic samples may improve the evaluation of marker-disease associations. However, data regarding the benefit of repeated samples in such studies are sparse. LÄS MER

7. 5. Clinical impact of epoetins in the treatment of anemia with special emphasis on patients with lymphoid malignancies. : dosing, iron supplementation and safety

   Författare :Michael Hedenus; Jack Lindh; Anders Österborg; Robert Hast; Umeå universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; anemia; cancer; lymphoproliferative malignancies; erythropoietin; intravenous iron; safety; Oncology; Onkologi; Oncology; onkologi;

   Sammanfattning : The aim of this thesis was to determine the relevant dose of arbepoetin-alfa (DA) in patients with lymphoproliferative diseases (LPD) and chemotherapy induced anemia (CIA), to study the clinical impact of intravenous (IV) iron supplementation combined with epoetin beta treatment, to identify factors that might predict hemoglobin (Hb) response to treatment with epoetins and to investigate safety of DA.A dose-finding phase II study was able to assess a reasonable DA dose of 2. LÄS MER